Today's Paper Latest News Local News Sports Coronavirus Viewpoints Arkansas News National News Obits Newsletters

Clinical drug trial to be held at Camden clinic

by Rhett Gentry | May 3, 2021 at 8:22 a.m.
This illustration provided by the Centers for Disease Control and Prevention shows the 2019 Novel Coronavirus (2019-nCoV). (Photo by Associated Press)

A clinical trial to combat COVID-19 in the Black community is coming to Camden, with Family Nurse Practitioner LaShonda Traylor leading the charge at Health Care Consulting PLLC.

Dr. Lane Rolling, an infectious disease specialist and COVID-19 Health Care Task Force of the Congressional Black Caucus member, reached out to Traylor about starting a clinical trial in Camden to treat Black residents who have contracted the virus, she said.

Traylor stated that the trial will be testing medication called NOviricid, a fast-acting nitrous oxide therapeutic with anti-viral properties which widens blood vessels to increase blood flow. NOviricid will only be given to patients who are COVID-19 positive and have consented to take part in the study.

The U.S. National Library of Medicine’s (NLM) Clinical Trial website states that the purpose of the study is to find out the side effects of the drug.

“If this study shows that the drug has no or few acceptable side effects, it will then include up to 840 participants to find out if the drug can reduce bad outcomes of COVID-19 infection (hospitalization, ICU admission, death). In each part of the study, half of the subjects will receive the study drug and the other half will be given a placebo (inactive pill),” the NLM website reads.

The sponsor for the study is Nitric Oxide Innovations LLC, a clinical stage biotechnology company founded in 2018. Rolling joined Nitric Oxide Innovations LLC in February this year as the company’s Chief Science Officer.

Treating Black residents is of great importance to Traylor, who expressed many of her patients’ concerns when seeing other providers.

“Their biggest complaint is not just the lack of access to quality care, it’s the treatment they feel they will receive once they go inside of the office of some physicians,” said Traylor.

She stated that patients she has treated have complained about their lack of care at other facilities, where doctors and nurse practitioners did not take blood work, examine the feet of diabetics or even listen to the lungs of the patients.

She also stated that her patients complained that prescriptions were often given by other doctors and that the lack of physical examinations made them both question the validity of the care they received and made them feel like their provider did not care about them.

“How do you have a conscience as a provider to do that to someone?” said Traylor. “I do everything I can do on my end for my patients, but for a lot of patients, it’s a huge concern and that is why they leave their providers.”

Rolling is scheduled to make a trip to Camden on May 17, and Traylor said she hopes that the clinical trial will bring positive results to those affected by COVID-19 in the community.


Sponsor Content